Skip to main content
Fig. 1 | Pilot and Feasibility Studies

Fig. 1

From: Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19

Fig. 1

NK cell characterization. A The flow cytometry data for CD56 and CD3 double staining. B The observation of NK cells expansion in two magnifications. C The healthy donors’ information. General description of graphs: Generally: the red bullets are for dead patients and green tonnages are for improved patients, the circular bullets are for female patients and the square bullets are for male patients. In the control group: 1st hospitalization (H), the median date of the treatment period (M), and discharge or death date (D), in the intervention group: 1st hospitalization date (H), 24 (− 1, + 1), and 48 (− 2, + 2) hours before and after cell infusion (CELL)

Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784